Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka 543-0027, Japan. firstname.lastname@example.org.
Background/Aim: We aimed to examine the relationship between antibodies to hepatitis B core antigen (anti-HBc) positivity and survival in patients with non-B non-C hepatocellular carcinoma (NBNC-HCC) who underwent curative treatment.
PATIENTS AND METHODS:
A total of 260 patients with NBNC-HCC who underwent curative therapy were analyzed. They included 124 anti-HBc-positive patients (47.7%) and 136 anti-HBc-negative patients (52.3%). Overall survival (OS) and recurrence-free survival (RFS) rates were compared.
The 3-year cumulative OS rates were 75.9% in the anti-HBc-positive group and 82.3% in the anti-HBc-negative group (p=0.069). The corresponding RFS rates were 29.8% in the anti-HBc-positive group and 43.0% in the anti-HBc-negative group (p=0.001). Multivariate analyses identified anti-HBc positivity (p=0.006), aspartate aminotransferase ≥40 IU/l (p=0.037) and des-γ-carboxy prothrombin ≥100 mAU/ml (p=0.046) as significant adverse predictors were linked to RFS.
Anti-HBc positivity can be a useful predictor for recurrence in patients with NBNC-HCC after curative therapy.